New Era for Treatment of Extensive-disease Small-cell Lung Cancer

DOI Web Site 15 References Open Access
  • Tsubata Yukari
    Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine

Bibliographic Information

Other Title
  • 肺癌診療アップデート：進展型小細胞肺癌

Search this article

Description

<p>Chemotherapy is the standard treatment for extensive-disease small-cell lung cancer. However, no significant prolongation of the survival has been observed over the last 30 years, and many literature reviews have shown that new therapies are less effective in prolonging the survival than cisplatin plus etoposide or CPT-11. In 2018, the addition of atezolizumab, an anti-PD-L1 antibody, to carboplatin plus etoposide combination therapy was shown to prolong the survival and became one of the standard treatments, and durvalumab is now also used as an anti-PD-L1 inhibitor. In this article, I would like to describe the transition of treatment for extensive-disease small-cell lung cancer and highlight the latest treatment regimen, supportive care required for management and the approach to making decisions concerning treatment.</p>

Journal

  • Haigan

    Haigan 61 (5), 371-376, 2021-10-20

    The Japan Lung Cancer Society

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top